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Abstract The C7-cyclitol 2-epi-5-epi-valiolone is the ¢rst pre-
cursor of the cyclitol moiety of the K-glucosidase inhibitor acar-
bose in Actinoplanes sp. SE50. The 2-epi-5-epi-valiolone be-
comes phosphorylated at C7 by the ATP dependent kinase
AcbM prior to the next modi¢cations. Preliminary data gave
evidences that the AcbO protein could catalyse the ¢rst modi¢-
cation step of 2-epi-5-epi-valiolone-7-phosphate. Therefore, the
AcbO protein, the encoding gene of which is also part of the
acbKMLNOC operon, was overproduced and puri¢ed. Indeed
the puri¢ed protein catalysed the 2-epimerisation of 2-epi-5-epi-
valiolone-7-phosphate. The chemical structure of the puri¢ed
reaction product was proven by nuclear magnetic resonance
spectroscopy to be 5-epi-valiolone-7-phosphate.
) 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The K-glucosidase inhibitor acarbose (a component of the
amylostatin complex; Fig. 1) is produced by strains of the
genera Actinoplanes and Streptomyces and inhibits various
K-glucosidases, especially in the intestine [1,2]. Acarbose is
produced industrially using developed strains of Actinoplanes
sp. SE50/110. It is built-up from three distinct moieties, an
unsaturated cyclitol (valienol), a 4-amino-4,6-dideoxyglucose
and a maltose unit, linked by (pseudo-)K-1,4 linkages. The
valienol and the 4-amino-4,6-dideoxyglucose are linked via
an N-glycosidic bond. This acarviosyl moiety is primarily re-
sponsible for the inhibitory e¡ect on K-glucosidases. Biosyn-
thetically, these compounds resemble aminoglycoside antibi-
otics [3,4]. Dependent on the C-sources in the fermentation
medium, Actinoplanes sp. SE50/110 produces also higher ho-
mologues of acarbose, which di¡er in the numbers of glucose
residues that are linked to the reducing and/or non-reducing
ends of the acarviosyl moiety. In our combined genetic and
biochemical studies of the biosynthesis of the pseudotetrasac-
charide acarbose we could show that 2-epi-5-epi-valiolone-7-
phosphate and dTDP-4-amino-4,6-dideoxyglucose are precur-
sors and that an activated pseudodisaccharide-phosphate,
dTDP-acarviosine-7-phosphate, is a possible intermediate in
the pathway (cf. Fig. 1) [5^8].
The C7-cyclitols like valienol, which can be regarded as
unsaturated sugar analogues, so called carbsugars, occur
both as secreted monomers (e.g. 2,3,4-trihydroxy-6-methylcy-
clohexanone and cyclophellitol) or as components in the nat-
ural compounds of the amylostatin-(acarbose) and validamy-
cin complexes were considered to be derived from similar
pathways; but recent evidence indicates also some di¡erences
[4,9^12]. The transition from the primary- to the secondary
metabolism in the cyclitol pathway in Actinoplanes sp. is cat-
alysed by the AcbC protein, a member of the dehydroquinate
synthase-related enzymes, in this case cyclising sedo-heptulose-
7-phosphate under formation of the C7-cyclitol 2-epi-5-epi-
valiolone [5]. This product is further processed by a kinase,
AcbM, to yield 2-epi-5-epi-valiolone-7-phosphate [6]. Here we
demonstrate that the next step in the biosynthesis of the va-
lienol (or valienamine) unit of acarbose is the epimerisation
to 5-epi-valiolone-7-phosphate, catalysed by the epimerase
AcbO.
2. Materials and methods
2.1. Bacterial strains, medium and growth conditions
Streptomyces lividans TK64 harbouring plasmids pCW4123M (ex-
pressing AcbM under control of the thiostrepton-inducible ptipA pro-
moter) or pMJO7 (expressing AcbO under control of the thiostrepton-
inducible ptipA promoter) were used in this study [6]. The strains were
grown in YEME [13] at 30‡C for 2 days and then 10 Wg/ml thiostrep-
ton was added in order to induce the overproduction of the AcbM or
AcbO proteins for another 24 h. Culture volumes of 100 ml were used
for enzyme preparations (see below) and constantly yielded 5 g of cells
(wet weight).
2.2. Preparation of cell free extracts
Cells of S. lividans overproducing AcbM or AcbO proteins were
harvested by centrifugation, washed twice and resuspended in the
disruption bu¡er (25 mM Tris^HCl, 10 mM MgCl2, 20 mM NH4Cl,
0.5 mM DTT, pH 7.6; 7.5 ml/5 g cells, wet weight). Cells were then
disrupted by sonication (2^3 min at 60 W). Cell free extracts were
obtained after centrifugation at 4‡C and 13 000Ug for 1 h. The ex-
tracts were dialysed against 5 l of the disruption bu¡er overnight at
4‡C. Protein concentrations were determined according to Bradford
[14] and were constantly in the range of 5 mg/ml in the crude extract.
The overproduction of Acb proteins was monitored by SDS^polyac-
rylamide gel electrophoresis (SDS^PAGE) as described previously [6].
2.3. Enzyme assays
Generally enzyme assays were performed in a standard bu¡er sys-
tem containing 25 mM Tris^HCl, 10 mM MgCl2, 20 mM NH4Cl, 10
mM ATP, 10 mM 2-epi-5-epi-valiolone, adjusted to pH 7.6. In each
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assay (¢nal volume 20 Wl), 16 Wl of the cell free extracts as prepared
above were used. The assays were incubated at 30‡C for 2^6 h. The
reaction was monitored by thin-layer chromatography (TLC).
2.4. TLC
Samples of the enzyme reactions were chromatographed on silica
thin-layer sheets (Merck, Darmstadt, Germany) using solvent I (bu-
tanol/ethanol/water, 9:7:4). The substrates were detected as blue spots
after development by use of a cerium- and molybdate-containing re-
agent [6].
2.5. Puri¢cation of His-tag AcbM and AcbO proteins
The puri¢cation of the His-tagged AcbM and AcbO proteins was
performed by use of Ni2þ-HiTrap chelating columns (Amersham Bio-
sciences, Freiburg, Germany) as described previously [6].
2.6. Preparation and puri¢cation of enzymatically formed
5-epi-valiolone-7-phosphate
Using the method described earlier [6], about 30 mg of enzymati-
cally synthesised and puri¢ed 2-epi-5-epi-valiolone was obtained. 30
mg of 2-epi-5-epi-valiolone was incubated with 6 ml of His-tag AcbM
protein enriched by Ni2þ-chelating (see above) in a bu¡er containing
25 mM Tris^HCl, 5 mM MgCl2, 20 mM NH4Cl, 15 mM ATP, 0.5
mM DTT, adjusted to pH 7.6, in a total volume of 10 ml. After
incubation at 30‡C for 6 h, the reaction mixture was heated at 95‡C
for 5 min, centrifuged (5000 rpm, 20 min) and then concentrated to
nearly 5 ml by lyophilisation. A sample of 10 ml of the Ni2þ-trapped
His-tag AcbO protein was added and the mixture was incubated at
30‡C for another 6 h. The reaction was monitored by TLC. After
heating at 95‡C for 5 min and centrifugation (5000 rpm, 20 min),
the reaction mixture was applied to an ultra¢ltration Amicon cell
with a YM-10 ultra¢ltration membrane (cut-o¡ 10 000 Da, Amicon,
Witten, Germany). The £ow-through was collected, concentrated to
3 ml by freeze-drying and then was applied to an anion-exchange chro-
matography on Dowex 1U8, Cl3form (mesh 100^200; Serva, Heidel-
berg, Germany) in a SR 25/50 column (Amersham-Biosciences, Frei-
burg, Germany). The column was washed with an excess amount of
water and the product was subsequently eluted with a linear gradient
of 0^600 mM of NaCl (£ow rate, 2 ml/min). The elution was collected
as 5 ml fractions and analysed by TLC. Fractions containing the
desired product were pooled (total volume 45 ml) and concentrated
to about 5 ml by freeze-drying. Desalting of the product was carried
out at 4‡C on a Sephadex G-10 (5.0U81 cm, SR25/100 column,
Amersham-Biosciences, Freiburg, Germany). The product was eluted
with water (£ow-rate, 1.5 ml/min). The fractions containing 5-epi-va-
liolone-7-phosphate were pooled (total volume of 50 ml). After lyo-
philisation a total recovery of 15 mg of 5-epi-valiolone-7-phosphate
was obtained as a light-yellow powder.
2.7. Nuclear magnetic resonance (NMR) spectroscopic
characterisation
All NMR spectra were recorded on a Bruker ARX 400 (400 MHz)
spectrometer. Besides 1H-, 13C-and 31P-experiments, also 2D COSY-
(1H^1H, 1H^13C as well as 1H^31P) and DEPT spectra for the corre-
lation of the hydrogen, carbon and phosphorus atoms were recorded.
The chemical shifts are given in ppm, related to the solvents as in-
ternal standard. External standards were used for 31P- (85% phos-
phoric acid) and 13C NMR (TMS).
Fig. 1. Acarbose biosynthesis in Actinoplanes sp. SE50/110. The scheme shows the postulated biosynthetic route [6]. The still unknown postu-
lated steps are symbolised by broken arrows.
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The multiplicity is given by the following symbols: s (singlet), d
(doublet), t (triplet), q (quartet), m (multiplet), 8t (pseudotriplet for
unresolved dd) and br (broad). The coupling constant J is given in
Hz.
NMR spectra: 5-epi-valiolone-7-phosphate. 1H^31P NMR (D2O,
pH=6.7, 400 MHz): N=2.73 (s, br, 2 H, exchange in D2O, H-6a
and H-6b), 3.58 (d, 1 H, J=10.2 Hz, H-7a), 3.88 (d, 1 H, J=10.2
Hz, H-7b), 3.89 (d, 1 H, J=9.7 Hz, H-4), 3.94 (8t, 1 H, H-3), 4.18 (d,
1 H, J=8.7 Hz, H-2). 13C NMR (D2O, pH=6.7, 101 MHz): N=49.13
(C-6), 66.87 (d, J=5.1 Hz, C-7), 75.33 (d, J=10.17 Hz, C-5), 75.88,
79.81 (C-3, C-4), 80.63 (C-2), 208.98 (C-1). 31P^1H NMR (D2O,
pH=6.7, 162 MHz): N=3.02 (PC-7). 1H NMR (D2O, pH adjusted
to 3.5 with d4-AcOH, 400 MHz): N=2.75 (s, br, 2 H, exchange in
D2O, H-6a and H-6b), 3.60 (dd, 1 H, J=4.3 Hz, J=9.9 Hz, H-7a),
3.81 (8t, 1 H, J=9.9 Hz, H-3), 3.92 (d, 1 H, J=10.2 Hz, H-4), 3.96
(dd, 1 H, J=4.1 Hz, J=10.6 Hz, H-7b), 4.17 (d, 1 H, J=9.2 Hz,
H-2).
3. Results and discussion
3.1. Puri¢cation and testing of an N-terminal His-tag AcbO
fusion protein
In a preceding publication we had noted that the product of
the kinase AcbM, 2-epi-5-epi-valiolone-7-phosphate (cf. Fig.
1), was further converted by a crude extract from a strain
producing recombinant AcbO protein to another C7-cyclitol-
phosphate with unchanged mass [6]. The construction of
a recombinant overexpressing strain of S. lividans TK64/
pMJO7, producing an N-terminally His-tagged AcbO protein
had also been described. We preliminarily postulated that the
AcbO product was an epimer, 5-epi-valiolone-7-phosphate, of
the substrate rather than being another epimer or a cyclitol in
which the phosphate group had been shifted to another hy-
droxyl group. Therefore, we sat out to verify this hypothesis
by using puri¢ed enzyme and preparing the product in a larg-
er scale for further structural analysis. The His-tag AcbO
protein was expressed under the control of an inducible pro-
moter (ptipA) which only led to moderate but visible over-
production (Fig. 2). The protein was largely enriched via pas-
sage over Ni2þ-chelation and elution; minor bands were still
to be seen in the SDS^PAGE analyses (cf. Fig. 2). The ap-
parent molecular weight of the puri¢ed His-tag AcbO protein
(29.5 kDa) was in good accordance with the estimation from
the protein sequence of 30.616 kDa. With this enzyme prep-
aration coupled assays were performed including chemically
synthesised racemic 2-epi-5-epi-valiolone and His-tag AcbM
kinase (crude extract or puri¢ed from S. lividans TK64/
pCW4123M), in combination without or with His-tag AcbO
protein. These assays clearly demonstrated that the puri¢ed
His-tag AcbO protein is actively converting the product of the
AcbM-catalysed reaction in absence of any other cofactor or
coenzyme, as can be seen from the TLC analyses (Fig. 3).
3.2. The AcbO protein is a 2-epi-5-epi-valiolone-7-phosphate
2-epimerase
Preparative isolation of the AcbO product was achieved by
scaling-up the assay for conversion of 30 mg 2-epi-5-epi-valio-
lone in the coupled 2-step reaction (see Section 2). The yield
after the ¢nal puri¢cation was a total of 15 mg of C7-cyclitol
phosphates. A 1H-NMR spectrum of the isolated reaction
product besides the educt showed a new product in a ratio
of 2:8. Obviously, the AcbO-catalysed conversion was at equi-
librium at 80% conversion of 2-epi-5-epi-valiolone-7-phos-
phate as further treatment with more enzyme did not change
this ratio. Subsequent extensive NMR analysis by monitoring
1H-, 13C-, 31P-, and two-dimensional 1H^1H, 1H^13C, and
1H^31P COSY spectra of the sodium salt unequivocally dem-
onstrated that the C7-phosphate group had been retained and
that the coupling pattern of the new product was consistent
with an epimerisation at the C-2 position by AcbO resulting in
5-epi-valiolone-7-phosphate as the major component in the
resulting mixture. In detail the results of a comparative
NMR spectroscopic analysis of the product and educt were
the following: In the product the cross-peaks from the 1H^31P
COSY experiment with the product proved that the phos-
phate at 3.02 ppm was correlated with H-7a and H-7b and,
therefore, still was attached to the branching methylene
group. Thus no shift of the phosphate ester grouping, e.g.
by a mutase-type reaction, had occurred. The signal pattern
for the ring protons of the product in the 1H NMR, however,
had changed signi¢cantly as compared to the educt (Fig. 4).
Resonances for all groups, except for the methylene group
had been strongly shifted up¢eld. All ring protons show cou-
pling constants around 3J=9^10 Hz, which is indicative for
the protons H-2, H-3, and H-4 being in axial orientation. This
proved that the conformation 2b is then selected because it is
clearly favoured over 2a (cf. Fig. 4). This phenomenon was
already observed in previous studies [7,11]. In the 1H NMR
the H-2 and H-3 occurred as a doublet at 4.18 ppm (coupling
constant 3J=8.7 Hz) and as a pseudotriplet at 3.94 ppm,
respectively. For better resolution of the coupling pattern of
all signals the pH of the NMR probe was shifted to 3.5, at
which the H-3 and H-4 signals were clearer separated from the
others and, therefore, could more easily be analysed. Under
such conditions a NOE irradiation at H-2 (W4.2 ppm) en-
hanced the H-4 signal con¢rming the spatially close correla-
tion between the two protons and ruling out the possibility
that 2-epi-5-epi-valiolone-7-phosphate had been converted to
Fig. 2. Puri¢cation of the His-tagged AcbM protein. The SDS-
PAGE analysis of cell free extracts and of the puri¢ed AcbO pro-
tein is shown (see Section 2). The lanes contain: 1, S. lividans
TK64/pIJ4123 (control); 2, S. lividans TK64/pMJO7 (acbO) ; 3, mo-
lecular weight marker, the respective molar masses of the protein
bands are shown; 4, puri¢ed His-tagged AcbO.
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2-epi-valiolone-7-phosphate (via a retroaldol and recyclisation
reaction), which could probably adopt a boat conformation,
where the coupling constants of all ring protons should also
be about 9^10 Hz.
3.3. Conclusions
Taken together, the acbO gene of Actinoplanes sp. SE50/110
encodes a 2-epi-5-epi-valiolone-7-phosphate 2-epimerase,
which clearly seems to catalyse an essential step in the con-
version of the primary metabolic precursor sedo-heptulose-7-
phosphate to the valienol moiety of the secondary metabolite
acarbose (cf. Fig. 1) [6,7]. Structurally these C7-cyclitol (phos-
phate) intermediates, with a keto group in position 1 of the
ring, obviously have a high stability, such that no measurable
keto-enol tautomerisation occurs which could spontaneously
epimerise the adjacent hydroxyl in ring position 2 under phys-
iological conditions. The primary structure of the AcbO pro-
tein (cf. accession number Y18523 in the EMBL data base)
does not show any signi¢cant similarity to other proteins with
known function and does not give any indication to the use of
a cofactor or a coenzyme, such as, e.g. NAD(P)þ. Therefore,
with the AcbO protein a new subclass of epimerases acting on
carbohydrates and derivatives (EC 5.1.3.^) is described. The
exact mechanism of this epimerisation remains unclear so far.
However, the presence of the ketogroup at C1 might be nec-
essary for this epimerisation mechanism.
For the speci¢c design of the acarbose pathway this
particular step could have several meanings: (i) the 5-epi-
valiolone-7-phosphate could be more stable than its 2-epimer;
(ii) this con¢guration of the cyclitol precursor is necessary to
be preformed in this stage in order to create the immediate
valienol precursor; (iii) the AcbO product is structurally clos-
er related to other, more widely distributed natural ketocycli-
tols, such as, e.g. (2-deoxy)scyllo-inosose occurring in both
anabolic and catabolic C6-cyclitol pathways [4]. Therefore
it could be an analogous substrate of an enzyme available
by chance during the individual evolution of this pathway
[15] ; for instance, it likely was a better substrate for the an-
cestral downstream enzyme, which either should have been
a cyclitol 5,6-dehydratase or 2-keto-reductase according to
the proposed pathway and was adopted to change its sub-
strate pro¢le to the particular types of C7-cyclitols we see
here [6,8].
The description of the procedures for gaining preparative
amounts of the products of the AcbC-, AcbM-, and AcbO-
catalysed biosynthetic steps, the ‘upper 2-epi-5-epi-valiolone
pathway’ (cf. Fig. 1) ([5,6] ; this paper), will largely facilitate
the further analysis of this unusual biosynthetic route yielding
a carbsugar unit structurally homologous to the universal
hexose L-D-glucose and replacing it in natural products which
are structural analogues of either dextrins (the amylostatins;
acarbose) or trehalose (validamycins).
Fig. 3. TLC analysis of the AcbO-catalysed epimerisation of 2-epi-5-epi-valiolone-7-phosphate. The details are described in Section 2. The lanes
contain: 1, puri¢ed 2-epi-5-epi-valiolone; 2, AcbM-catalysed phosphorylation by the puri¢ed His-tagged AcbM protein (cf. [6]) ; 3, reaction
from lane 2 plus puri¢ed AcbO protein; 4, the puri¢ed reaction product from lane 3 after gel ¢ltration. Arrows mark the respective com-
pounds; a small impurity of unknown structure (degradation product?) was detected in lanes 1^3.
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